Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome

doi:10.4330/wjc.v16.i6.329

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (552)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

241

Figures (1-2)

Tables (1-4)

Sum=359

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=138

Publishing Process of This Article

Item

Count

Browse

Download

Sum=30

Jun 26, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Cardiol. Jun 26, 2024; 16(6): 329-338
Published online Jun 26, 2024. doi: 10.4330/wjc.v16.i6.329

Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome

Yasuhiko Saeki, Jun Sawaguchi, Satori Akita, Taka-aki Takamura, Kosuke Fujibayashi, Minoru Wakasa, Hironobu Akao, Michihiko Kitayama, Yasuyuki Kawai, Kouji Kajinami

Yasuhiko Saeki, Jun Sawaguchi, Satori Akita, Taka-aki Takamura, Kosuke Fujibayashi, Minoru Wakasa, Hironobu Akao, Yasuyuki Kawai, Kouji Kajinami, Department of Cardiology, Kanazawa Medical University, Uchinada 9200293, Japan

Michihiko Kitayama, Trans-catheter Cardiovascular Therapeutics, Kanazawa Medical University, Uchinada 9200293, Japan

Author contributions: Saeki Y contributed to principal investigator (conceptualization, data curation, formal data analysis and interpretation, and drafting of the manuscript); Sawaguchi J contributed to associate investigator (conceptualization, data curation, formal data analysis, and interpretation); Takamura TA, Kitayama M, and Kawai Y contributed to coronary interventionalists (data curation and project administration regarding percutaneous coronary intervention procedures and patient management); Akita S, Fujibayashi K, Wakasa M, and Akao H contributed to staff cardiologists (data curation, preliminary data analysis, and interpretation); Kajinami K contributed to director (supervision of the overall study and manuscript editing/finalization).

Supported by the Vehicle Racing Commemorative Foundation, No. 2013–2015; Grant for Collaborative Research from Kanazawa Medical University, No. C2015-4; and Grants-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science to Dr. Kouji Kajinami, No. 18K08051 and No. 21K08139.

Institutional review board statement: The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of our institution (Approval No. I-115).

Informed consent statement: Written informed consent was obtained from all patients prior to enrollment.

Conflict-of-interest statement: There are no conflicts of interest to disclose.

Data sharing statement: Data used to support the findings of this study are available from the corresponding author upon request.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Kouji Kajinami, FACP, FAHA, MD, Professor, Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada 9200293, Japan. kajinami@kanazawa-med.ac.jp

Received: February 6, 2024
Revised: April 22, 2024
Accepted: April 28, 2024
Published online: June 26, 2024
Processing time: 140 Days and 5.6 Hours

Core Tip

Core Tip: Two hundred and forty-nine patients with acute coronary syndrome were enrolled in the study. Lipoprotein(a) [Lp(a)] levels were measured before percutaneous coronary intervention (PCI) to 48 h after using an isoform-independent assay. Lp(a) levels decreased significantly from pre-PCI (0 h) to 12 h after, and then increased up to 48 h after. The changes from 0 to 12 h [Lp(a)Δ0-12] were significantly correlated with basal creatinine and Lp(a). Among the tertiles classified according to the changes from 0 to 12 h [Lp(a)Δ0-12], major adverse cardiac events (MACE) were significantly more frequent in the lowest Lp(a)Δ0-12 group than in the other two groups. Multivariate analysis revealed that Lp(a)Δ0-12 and basal creatinine were independent determinants of subsequent MACE.